Cargando…

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease

Alzheimer’s disease (AD) is the most common cause of dementia among older adults. Accumulation of amyloid-β (Aβ) in the brain is considered central in AD pathogenesis and its understanding crucial for developing new diagnostic and therapeutic approaches. Recent literature suggests that ageing may in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moro, Maria Luisa, Phillips, Andrew Stephen, Gaimster, Katie, Paul, Christian, Mudher, Amritpal, Nicoll, James A. R., Boche, Delphine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753481/ https://www.ncbi.nlm.nih.gov/pubmed/29298722 http://dx.doi.org/10.1186/s40478-017-0505-x

Ejemplares similares

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease
por: Zagorski, Karen, et al.
Publicado: (2023)

An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta
por: Vukicevic, M., et al.
Publicado: (2022)

Isoaspartate and neurodegeneration
por: Wang, Jijing, et al.
Publicado: (2022)

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013)

Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome
por: De Kimpe, Line, et al.
Publicado: (2012)

Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology
por: Gnoth, Kathrin, et al.
Publicado: (2020)

Role of the Fast Kinetics of Pyroglutamate-Modified Amyloid-β Oligomers in Membrane Binding and Membrane Permeability
por: Lee, Joon, et al.
Publicado: (2014)

Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits
por: Chatterjee, Shreyasi, et al.
Publicado: (2018)

Activity and Architecture of Pyroglutamate-Modified Amyloid-β (Aβ(pE3-42)) Pores
por: Gillman, Alan L., et al.
Publicado: (2014)

Molecular Mechanisms of Microglial Motility: Changes in Ageing and Alzheimer’s Disease
por: Franco-Bocanegra, Diana K., et al.
Publicado: (2019)

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease
por: Nicoll, James A R, et al.
Publicado: (2019)

Innate immunity in Alzheimer’s disease: the relevance of animal models?
por: Franco Bocanegra, Diana K., et al.
Publicado: (2017)

First Immunoassay for Measuring Isoaspartate in Human Serum Albumin
por: Wang, Jijing, et al.
Publicado: (2021)

Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
por: Zotova, Elina, et al.
Publicado: (2010)

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
por: Bayer, Thomas A.
Publicado: (2021)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
por: Dammers, Christina, et al.
Publicado: (2015)

Investigating Interventions in Alzheimer's Disease with Computer Simulation Models
por: Proctor, Carole J., et al.
Publicado: (2013)

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
por: Jäkel, Lieke, et al.
Publicado: (2019)

Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β(3-42) peptide
por: Cho, Illhwan, et al.
Publicado: (2023)

Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
por: Frost, Jeffrey L., et al.
Publicado: (2012)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer’s Disease
por: Domingo, Guido, et al.
Publicado: (2021)

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
por: Crehan, Helen, et al.
Publicado: (2020)

Metabolic Acidosis Due To Pyroglutamic Acid
por: Serpa, Maria João, et al.
Publicado: (2018)

Flucloxacillin and paracetamol induced pyroglutamic acidosis
por: Zand Irani, Anis, et al.
Publicado: (2021)

Curcumin as a Holistic Treatment for Tau Pathology
por: Sivanantharajah, Lovesha, et al.
Publicado: (2022)

Systemic infection modifies the neuroinflammatory response in late stage Alzheimer’s disease
por: Rakic, Sonja, et al.
Publicado: (2018)

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice
por: Dunkelmann, Tina, et al.
Publicado: (2018)

The Beta-Amyloid Protein of Alzheimer's Disease: Communication Breakdown by Modifying the Neuronal Cytoskeleton
por: Mokhtar, Sara H., et al.
Publicado: (2013)

Modulation of aggregation and structural polymorphisms of β-amyloid fibrils in cellular environments by pyroglutamate-3 variant cross-seeding
por: Cruceta, Letticia, et al.
Publicado: (2023)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

The mitochondrial protein TSPO in Alzheimer’s disease: relation to the severity of AD pathology and the neuroinflammatory environment
por: Garland, Emma F., et al.
Publicado: (2023)

Elevated expression of protein-L-isoaspartate O-methyltransferase-1 (PCMT1) in cervical cancer
por: Shan, Liyun, et al.
Publicado: (2022)

Microglial immunophenotype in dementia with Alzheimer’s pathology
por: Minett, Thais, et al.
Publicado: (2016)

Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study
por: Franco-Bocanegra, Diana K., et al.
Publicado: (2019)

Microglial morphology in Alzheimer’s disease and after Aβ immunotherapy
por: Franco-Bocanegra, Diana K., et al.
Publicado: (2021)

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
por: Wirths, Oliver, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ojvpkccmt88bkbr7mpjlgthuh6